Педиатрическая фармакология (Jan 2020)
Prioritizing Research Challenges and Funding for Allergy and Asthma and the Need for Translational Research — The European Strategic Forum on Allergic Diseases
- I. Agache,
- I. Annesi-Maesano,
- A. Bonertz,
- F. Branca,
- A. Cant,
- Z. Fras,
- F. Ingenrieth,
- L. Namazova-Baranova,
- M. Odemyr,
- A. Spanevello,
- S. Vieths,
- A. Yorgancioglu,
- M. Alvaro-Lozano,
- D. Barber Hernandez,
- T. Chivato,
- S. Del Giacco,
- Z. Diamant,
- I. Eguiluz-Gracia,
- R. G. van Wijk,
- P. Gevaert,
- A. Graessel,
- P. Hellings,
- K. Hoffmann-Sommergruber,
- M. Jutel,
- S. Lau,
- A. Lauerma,
- J. Maria Olaguibel,
- L. O’Mahony,
- C. Ozdemir,
- O. Palomares,
- O. Pfaar,
- J. Sastre,
- G. Scadding,
- C. Schmidt-Weber,
- P. Schmid-Grendelmeier,
- M. Shamji,
- I. Skypala,
- M. Spinola,
- O. Spranger,
- M. Torres,
- A. Vereda,
- S. Bonini
Affiliations
- I. Agache
- Transylvania University
- I. Annesi-Maesano
- Medical School Saint Antoine, IPLESP, INSERM and Sorbonne Université
- A. Bonertz
- Federal Agency for Vaccines and Biomedicines, Paul‐Ehrlich‐Institut
- F. Branca
- Department of Nutrition for Health and Development; WHO/HQ
- A. Cant
- University of Newcastle Upon Tyne, Newcastle upon Tyne, UK; European Society for Immunodeficiencies, Geneva, Switzerland
- Z. Fras
- University Medical Centre Ljubljana; University of Ljubljana; UEMS — Union Europeenne des Medecins Specialistes/European Union of Medical Specialists, Brussels, Belgium
- F. Ingenrieth
- SCOPE Europe
- L. Namazova-Baranova
- Russian National Research Medical University of MoH RF; Central Clinical Hospital of MoSHE (Ministry of Science and High Education)
- M. Odemyr
- European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)
- A. Spanevello
- Università degli Studi dell’Insubria; Istituti Clinici Scientifici Maugeri, IRCCS Tradate
- S. Vieths
- Federal Agency for Vaccines and Biomedicines, Paul‐Ehrlich‐Institut
- A. Yorgancioglu
- Celal Bayar University School of Medicine
- M. Alvaro-Lozano
- Hospital Sant Joan de Déu
- D. Barber Hernandez
- Universidad CEU San Pablo; Instituto de Salud Carlos III
- T. Chivato
- University CEU San Pablo
- S. Del Giacco
- University of Cagliari
- Z. Diamant
- Lund University, Sweden; Charles University and Thomayer Hospital, Czech Republic
- I. Eguiluz-Gracia
- UMA, Malaga; Carlos III Health Institute, Madrid
- R. G. van Wijk
- Erasmus Medical Center
- P. Gevaert
- Ghent University
- A. Graessel
- Allergy Therapeutics, Worthing, UK; Bencard Allergie GmbH, Munich, Germany
- P. Hellings
- Ghent University, Belgium; UZ Leuven, Belgium; Academic Medical Center, Amsterdam, The Netherlands
- K. Hoffmann-Sommergruber
- Medical University of Vienna
- M. Jutel
- Wroclaw Medical University; “ALL‐MED” Medical Research Institute
- S. Lau
- Charité Universität Medizin
- A. Lauerma
- Dermatology and Allergology, Helsinki University Hospital; University of Helsinki
- J. Maria Olaguibel
- Complejo Hospitalario de Navarra
- L. O’Mahony
- National University of Ireland
- C. Ozdemir
- Istanbul University
- O. Palomares
- Complutense University of Madrid
- O. Pfaar
- University Hospital Marburg, Philipps‐Universität Marburg
- J. Sastre
- Fundación Jimenez Diaz; Instituto Carlos III, CIBERES, Universidad Autónoma de Madrid
- G. Scadding
- RNTNE Hospital
- C. Schmidt-Weber
- Technische Universität und Helmholtz Zentrum
- P. Schmid-Grendelmeier
- University Hospital of Zurich; Christine‐Kühne Center for Allergy Research and Education CK‐CARE Davos
- M. Shamji
- Allergy & Clinical Immunology, Inflammation, Repair and Development, Imperial College, National Heart and Lung Institute, Immunomodulation and Tolerance Group; Asthma UK Centre in Allergic Mechanisms of Asthma
- I. Skypala
- Royal Brompton & Harefield NHS Foundation Trust; Imperial College
- M. Spinola
- European Medical Affairs, Sanofi
- O. Spranger
- Global Allergy and Asthma Patient Platform
- M. Torres
- Allergy Unit, IBIMA, Regional University Hospital of Malaga, UMA, Malaga; Carlos III Health Institute, Madrid
- A. Vereda
- Aimmune Therapeutics
- S. Bonini
- Institute of Translational Pharmacology, Italian National Research Council
- DOI
- https://doi.org/10.15690/pf.v16i5.2058
- Journal volume & issue
-
Vol. 16,
no. 5
pp. 281 – 295
Abstract
The European Academy of Allergy and Clinical Immunology (EAACI) organized the first European Strategic Forum on Allergic Diseases and Asthma. The main aim was to bring together all relevant stakeholders and decision‐makers in the field of allergy, asthma and clinical Immunology around an open debate on contemporary challenges and potential solutions for the next decade. The Strategic Forum was an upscaling of the EAACI White Paper aiming to integrate the Academy’s output with the perspective offered by EAACI’s partners. This collaboration is fundamental for adapting and integrating allergy and asthma care into the context of real‐world problems. The Strategic Forum on Allergic Diseases brought together all partners who have the drive and the influence to make positive change: national and international societies, patients’ organizations, regulatory bodies and industry representatives. An open debate with a special focus on drug development and biomedical engineering, big data and information technology and allergic diseases and asthma in the context of environmental health concluded that connecting science with the transformation of care and a joint agreement between all partners on priorities and needs are essential to ensure a better management of allergic diseases and asthma in the advent of precision medicine together with global access to innovative and affordable diagnostics and therapeutics.
Keywords
- allergic diseases
- asthma
- big data
- environmental health
- exposome
- implementation science
- quality criteria
- translational research
